Pharmacyclics’ Ibrutinib Scoops Another FDA Breakthrough Designation, And Pfizer Joins The Club
Pharmacyclics and partner J&J announce a third breakthrough therapy designation from FDA for ibrutinib for hard-to-treat CLL patients with the 17p deletion. Also, NIH investigators report positive Phase II data confirming single-agent activity at the AACR meeting in Washington, D.C.
You may also be interested in...
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.
Pharmacyclics/Janssen’s Imbruvica carries a high list price, but also patient support.
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.